New Drug: Tarlatamab for SCLC
Study
| Phase 2, open-label (DeLLphi-301) |
| Relapsed/refractory to platinum-based therapy Advanced SCLC |
| Tarlatamamab 10 or 100 mg => Final dose selected as 10 mg |
Efficacy
| ORR: 40% [29%-52%] |
| mDoR: 9.7 mos |
| mPFS: 4.9 mos in 10 mg group |
Safety
| Cytokine release syndrome: 52% in 10 mg group |
| ICANS: 9 % in 10 mg group |
| Any grade >=3 AE: 60% |
N Engl J Med 2023;389:2063-2075
Ahn MJ Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
http://doi.org/10.1056/NEJMoa2307980
Reviewed by Ulas D. Bayraktar, MD on Jun 24, 2024
